Richardson Financial Services Inc. Has $119,000 Position in Pfizer Inc. $PFE

Richardson Financial Services Inc. increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,762 shares of the biopharmaceutical company’s stock after buying an additional 605 shares during the quarter. Richardson Financial Services Inc.’s holdings in Pfizer were worth $119,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of PFE. Pacer Advisors Inc. boosted its stake in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after buying an additional 17,957,928 shares during the period. Amundi boosted its position in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC acquired a new stake in Pfizer during the first quarter valued at $389,861,000. Goldman Sachs Group Inc. boosted its position in Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after purchasing an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after buying an additional 4,629,976 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several research reports. Morgan Stanley reduced their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.35.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.81 on Friday. The firm has a fifty day simple moving average of $24.86 and a 200-day simple moving average of $24.13. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.82. The stock has a market capitalization of $141.03 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.